Akademik Veri Yönetim Sistemi
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.17, sa.1, ss.55-64, 2007 (Scopus)
Mortality from breast cancer has gradually declined despite a rising in incidence during the last two decades due to more widespread screening methods such as mammography. This increase in survival can be attributed in large part to the widespread use of adjuvant medical therapy after surgery. Adjuvant chemotherapy and endocrine therapy improves the disease-free survival and overall survival in patients with early stage breast cancer. Today, it is a standard clinical practice to administer adjuvant systemic therapy to patients with node-positive and high-risk, node-negative breast cancer. Anthracycline-based chemotherapy regimens are widely used as a part of systemic treatment. Recently, many trials that incorporating taxanes into the adjuvant treatment plan to increase the efficacy have been performed. This review is prepared to summarize the adjuvant trials that performed with taxanes at the different dosing and schedules.